MX2017000831A - Cuantificacion de tnfr2 : fc plegada erroneamente. - Google Patents

Cuantificacion de tnfr2 : fc plegada erroneamente.

Info

Publication number
MX2017000831A
MX2017000831A MX2017000831A MX2017000831A MX2017000831A MX 2017000831 A MX2017000831 A MX 2017000831A MX 2017000831 A MX2017000831 A MX 2017000831A MX 2017000831 A MX2017000831 A MX 2017000831A MX 2017000831 A MX2017000831 A MX 2017000831A
Authority
MX
Mexico
Prior art keywords
tnfr2
misfolded
quantification
wrongly
determining
Prior art date
Application number
MX2017000831A
Other languages
English (en)
Inventor
RUPPRECHTER Alfred
Fuchs Michael
LAMANNA William
Holzmann Johann
Toll Hansjörg
Mayer Robert
Posch Christoph
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51210344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017000831(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of MX2017000831A publication Critical patent/MX2017000831A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/20—Post-translational modifications [PTMs] in chemical analysis of biological material formation of disulphide bridges

Abstract

La presente invención se refiere a métodos para determinar la cantidad relativa de TNFR2:Fc con puentes de disulfuro erróneos en una muestra de TNFR2:Fc, que es una proteína de fusión utilizada en una variedad de aplicaciones terapéuticas. Además, la presente invención se refiere a un método para purificar TNFR2:Fc, en donde el método se utiliza para determinar el porcentaje de TNFR2:Fc con puentes de disulfuro erróneos, y a composiciones de TNFR2:Fc obtenidas por dicho método.
MX2017000831A 2014-07-18 2015-07-17 Cuantificacion de tnfr2 : fc plegada erroneamente. MX2017000831A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14177696.3A EP2975050B1 (en) 2014-07-18 2014-07-18 Quantification of misfolded TNFR2:Fc
PCT/EP2015/066385 WO2016009036A1 (en) 2014-07-18 2015-07-17 Quantification of misfolded tnfr2:fc

Publications (1)

Publication Number Publication Date
MX2017000831A true MX2017000831A (es) 2017-05-01

Family

ID=51210344

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000831A MX2017000831A (es) 2014-07-18 2015-07-17 Cuantificacion de tnfr2 : fc plegada erroneamente.

Country Status (10)

Country Link
US (2) US9598718B2 (es)
EP (1) EP2975050B1 (es)
KR (1) KR20170031145A (es)
AU (1) AU2015289100B2 (es)
BR (1) BR112017000955A2 (es)
CA (1) CA2952342A1 (es)
ES (1) ES2733298T3 (es)
MX (1) MX2017000831A (es)
RU (1) RU2698671C2 (es)
WO (1) WO2016009036A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
WO2023053032A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of fusion protein

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
WO2003102225A1 (en) * 2002-05-31 2003-12-11 Waters Investments Limited Destructible surfactants and uses thereof
WO2005012353A1 (en) 2003-08-01 2005-02-10 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
US7408030B2 (en) * 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
PT2061803T (pt) * 2006-08-28 2019-11-21 Ares Trading Sa Processo de purificação de proteinas contendo fc
US20110151494A1 (en) * 2008-06-30 2011-06-23 H. Lee Moffit Cancer & Research Institute Methods and materials for monitoring myeloma using quantitative mass spectrometry
SG185038A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
AU2011246504B2 (en) 2010-04-26 2013-09-26 Novartis Ag Improved cell culture medium
CN102382190B (zh) 2010-09-01 2014-04-09 山东新时代药业有限公司 分离和去除TNFR-Fc融合蛋白中寡聚体的方法
KR20140114278A (ko) * 2011-02-25 2014-09-26 머크 샤프 앤드 돔 코포레이션 변형된 ｏ-글리코실화를 갖는 단백질의 생산을 위한 효모 균주
WO2012176158A1 (en) 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
KR101454316B1 (ko) 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
BR112015005161A2 (pt) * 2012-09-11 2017-07-04 Coherus Biosciences Inc etanercepte corretamente dobrado em alta pureza e excelente rendimento
WO2014102814A1 (en) 2012-12-31 2014-07-03 Intas Biopharmaceuticals Limited Process for the purification of fc fusion proteins
ES2759061T3 (es) * 2013-03-15 2020-05-07 Biomolecular Holdings Llc Inmunoglobulina híbrida que contiene unión no peptidílica

Also Published As

Publication number Publication date
RU2017102487A3 (es) 2018-10-03
AU2015289100A1 (en) 2017-01-12
KR20170031145A (ko) 2017-03-20
RU2698671C2 (ru) 2019-08-28
ES2733298T3 (es) 2019-11-28
US9598718B2 (en) 2017-03-21
EP2975050B1 (en) 2019-05-29
EP2975050A1 (en) 2016-01-20
CA2952342A1 (en) 2016-01-21
AU2015289100B2 (en) 2019-08-15
WO2016009036A1 (en) 2016-01-21
BR112017000955A2 (pt) 2018-01-16
US20160017403A1 (en) 2016-01-21
RU2017102487A (ru) 2018-08-20
US9182410B1 (en) 2015-11-10

Similar Documents

Publication Publication Date Title
AU2020264349B2 (en) Anti-PVRIG antibodies and methods of use
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2016016886A (es) Anticuerpos anti-axl.
EA202092435A3 (ru) Моноклональные антитела против bcma
MX2022009875A (es) Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
EA201591515A1 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
PH12016501366A1 (en) Novel anti-baff antibodies
MX2016016883A (es) Anticuerpo anti-axl.
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
EA201691374A1 (ru) Инсулин длительного действия и его применение
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
PH12016501547A1 (en) Anti-il-13/il-17 bispecific antibodies and uses thereof
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201690992A1 (ru) Антитела, специфичные к fcrn
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
MX2017000831A (es) Cuantificacion de tnfr2 : fc plegada erroneamente.